EQL Pharma Beheer

Beheer criteriumcontroles 3/4

De CEO EQL Pharma is Axel Schorling, benoemd in Aug2022, heeft een ambtstermijn van 2.25 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 2.26M, bestaande uit 72.6% salaris en 27.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.07% van de aandelen van het bedrijf, ter waarde SEK 20.65M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 4.8 jaar.

Belangrijke informatie

Axel Schorling

Algemeen directeur

SEK 2.3m

Totale compensatie

Percentage CEO-salaris	72.6%
Dienstverband CEO	2.3yrs
Eigendom CEO	1.1%
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Oct 29

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22

Analyse CEO-vergoeding

Hoe is Axel Schorling's beloning veranderd ten opzichte van EQL Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	SEK 31m
Jun 30 2024	n/a	n/a	SEK 26m
Mar 31 2024	SEK 2m	SEK 2m	SEK 23m

Compensatie versus markt: De totale vergoeding ($USD 204.38K ) Axel } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 466.86K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Axel te vergelijken met de prestaties van het bedrijf.

CEO

Axel Schorling (38 yo)

2.3yrs

Tenure

SEK 2,262,000

Compensatie

Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christer Fahraeus	Founder & Chairman	18.8yrs	SEK 250.00k	geen gegevens
Axel Schorling	President & CEO	2.3yrs	SEK 2.26m	1.07% SEK 20.7m
Anna Jonsson	Chief Financial Officer	2.9yrs	geen gegevens	0.047% SEK 911.6k
Martin Kristofferson	Chief Operating Officer	2.3yrs	geen gegevens	0.070% SEK 1.3m
Alexander Brising	Chief Commercial Officer	no data	geen gegevens	0.88% SEK 17.0m
Carl Lindgren	Chief Business Development Officer	1.7yrs	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EQL wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christer Fahraeus	Founder & Chairman	18.8yrs	SEK 250.00k	geen gegevens
Linda Neckmar	Independent Director	4.8yrs	SEK 100.00k	0.0086% SEK 166.0k
Anders Mansson	Independent Director	6.3yrs	SEK 100.00k	0.034% SEK 664.1k
Per Svangren	Independent Director	3.8yrs	SEK 100.00k	0.034% SEK 664.1k
Per Ollermark	Independent Director	3.8yrs	SEK 100.00k	geen gegevens

4.8yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EQL wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

EQL Pharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Chief Operating Officer recently bought kr281k worth of stock

EQL Pharma AB (publ) Appoints Nikunj A. Shah as New Board Member

EQL Pharma AB (publ), Annual General Meeting, Aug 19, 2024

Insufficient new directors

EQL Pharma AB (publ), Annual General Meeting, Aug 17, 2023

Founder & Chairman recently sold kr11m worth of stock

Recent updates

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Chief Operating Officer recently bought kr281k worth of stock

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

EQL Pharma AB (publ) Appoints Nikunj A. Shah as New Board Member

EQL Pharma AB (publ) to Report Fiscal Year 2025 Results on May 08, 2025

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

First quarter 2025 earnings: Revenues exceed analyst expectations

EQL Pharma AB (publ), Annual General Meeting, Aug 19, 2024

EQL Pharma AB's Key Product Mellozzan[® ](melatonin) Receives Marketing Approval in Switzerland

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Investor sentiment improves as stock rises 16%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Eql Pharma AB (Publ) Provides Sales Guidance for the Year 2024/25

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Third quarter 2024 earnings released

Insufficient new directors

Second quarter 2024 earnings released: EPS: kr0.16 (vs kr0.26 in 2Q 2023)

EQL Pharma AB (publ) to Report Fiscal Year 2024 Results on May 14, 2024

New major risk - Earnings quality

Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)

EQL Pharma AB (publ) to Report Q1, 2024 Results on Aug 16, 2023

EQL Pharma AB (publ), Annual General Meeting, Aug 17, 2023

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Founder & Chairman recently sold kr11m worth of stock

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings released

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Second quarter 2023 earnings released: EPS: kr0.26 (vs kr0.18 in 2Q 2022)

EQL Pharma AB (publ) Launches One-Step "Lollipop" Antigen Self-Test for Covid-19 in the Nordics - All in One - One Device, One Step

First quarter 2023 earnings released

EQL Pharma AB (publ) Announces Executive Changes

EQL Pharma AB (publ) to Report Q3, 2023 Results on Feb 14, 2023

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Full year 2022 earnings released: EPS: kr1.09 (vs kr0.36 in FY 2021)

EQL Pharma Receives Approval of Glycopyrronium EQL Pharma Solution for Injection 0.2Mg/Ml from Danish Medicines Agency

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

EQL Pharma AB (publ) to Report Fiscal Year 2022 Results on May 13, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Full year 2021 earnings released: EPS kr0.36 (vs kr0.09 in FY 2020)

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

EQL Pharma AB (Publ) Announces Approval of Mellozzan (Melatonin)

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Third quarter 2021 earnings released

EQL Pharma AB (Publ) Convenes Nomination Committee

EQL Pharma Announces Approval of Glucosparc (Metformin)

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

New 90-day high: kr40.00

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: kr33.50

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Director recently sold kr285k worth of stock

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

EQL Pharma Receives a New Order for Consumables from a Hospital Region

Director recently sold kr2.8m worth of stock

Market bids up stock over the past week

Market pulls back on stock over the past week